AstraZeneca AI: Speeding Up Drug Discovery

AstraZeneca is now using artificial intelligence from the company Owkin to speed up drug discovery. This AI agent will analyze trials and forecast competitive activity. Here's the thing: AstraZeneca aims to improve research and development, as well as clinical trial work. They want to cut down the typical eight or nine years it takes for new drug discoveries. This move is part of AstraZeneca's larger AI strategy, which includes a pilot program with the U.S. Food and Drug Administration to improve early clinical trial efficiencies. What's interesting is that Owkin's AI agents will help AstraZeneca monitor and analyze competitive data from various sources. This includes ongoing clinical trials, completion timelines, and competitor strategies in specific disease areas. The system will even use patient data from 800 hospitals. The bottom line: This technology helps pharmaceutical companies make quicker decisions and gain new insights, potentially bringing new medicines to patients faster.